Showing results (421-430 of 503) with videos related to

Sort By:
Pageof 51
Future Oncology (London, England)|July 29, 2024
Quality of life in cemiplimab-treated patients with locally advanced basal cell carcinoma in a Phase II clinical trialAlexander J Stratigos, Chieh-I Chen, Cristina Ivanescu, et al.
Research Square|May 25, 2026
A high-penetrance intergenic variant at 9p21 confers melanoma susceptibilityMaria Teresa Landi, Linh Bui-Raborn, Lorenza Pastorino, et al.
Italian Journal of Dermatology and Venereology|June 6, 2023
Line-field confocal optical coherence tomography in melanocytic and non-melanocytic skin tumorsMariano Suppa, Gerardo Palmisano, Linda Tognetti, et al.
Clinical and Experimental Dermatology|June 27, 2025
Clinical Course of Atopic Dermatitis after Dupilumab Discontinuation: A Multicenter Real-World StudyFrancesca Barei, Stefano Macchi, Paolo Calzari, et al.
Journal of the American Academy of Dermatology|December 6, 2020
Immune checkpoint-mediated psoriasis: A multicenter European study of 115 patients from the European Network for Cutaneous Adverse Event to Oncologic Drugs (ENCADO) groupVasiliki Nikolaou, Vincent Sibaud, Davide Fattore, et al.
Pharmaceuticals (Basel, Switzerland)|October 26, 2024
Fast Clinical Response of Bimekizumab in Nail Psoriasis: A Retrospective Multicenter 36-Week Real-Life StudyElena Campione, Fabio Artosi, Ruslana Gaeta Shumak, et al.
The Oncologist|December 21, 2023
Hedgehog Inhibitors Beyond Clinical Complete Response in Basal Cell Carcinoma: Should I Stop or Should I Go?Salvatore Alfieri, Rebecca Romanò, Sara Marceglia, et al.
Clinics in Dermatology|November 17, 2021
The Effect of the COVID-19 Lockdown on Melanoma Diagnosis in ItalyGiulio Gualdi, Annamaria Porreca, Giuseppe Fabrizio Amoruso, et al.
International Journal of Dermatology|March 1, 2026
European Dermatologists' Perception and Awareness of Teledermatology Use: Results From an International Survey Promoted by the EADV Teledermatology Task ForceLinda Tognetti, Paola Pasquali, Elvira Moscarella, et al.
The Journal of Dermatological Treatment|January 23, 2026
Risankizumab super responders in moderate-to-severe psoriasis: prevalence, predictors, and long-term maintenance in a multicenter, international, real-world cohortDiego Orsini, Luca Potestio, Matteo Megna, et al.
Pageof 51